TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05647200
Drug: control: additional ringers during cardiopulmonary bypass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C): administration of 100 mL of Ringer's solution, first dose directly after aortic cross clamping and blood cardioplegia administration, second dose after the third blood cardioplegia administration (± 30 min after the first dose).
Study: NCT04708782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered QID
Study: NCT05620823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral; Tablet
Study: NCT06364930
Drug: Placebo 10mg Tab
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10mg Tab QD for 60 months.
Study: NCT06478251
Drug: NW-301V
Normalized name: DRESSING,HYDRASORB 4IN X 4IN KEN#1694-NW
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCR-T T cell targeting KRAS G12V mutation
Study: NCT06478251
Drug: NW-301D
Normalized name: DRESSING,HYDRASORB 4IN X 4IN KEN#1694-NW
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCR-T T cell targeting KRAS G12D mutation
Study: NCT04924114
Drug: MK-6194
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT04924114
Drug: MK-6194-matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT06159686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The application of the placebo cream occurred in the morning and evening on the itching areas, excluding the face for 4 weeks.
Study: NCT06414798
Drug: Drug: ABBV-1088
Approvals — FDA: no, EMA: no, PMDA: no
Description: • Oral Capsule
Study: NCT06414798
Drug: Drug: Placebo for ABBV-1088
Approvals — FDA: no, EMA: no, PMDA: no
Description: • Oral Capsule
Study: NCT05388929
Drug: Standard Opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard opioid after surgery or at discharge
Study: NCT05719558
Drug: ASP1002
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous (IV) infusion
Study: NCT06567769
Drug: GC1130A
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICV injection
Study: NCT05636293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06541691
Drug: Plain aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain aspirin tablet 81 mg, once daily
Study: NCT05891496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to semaglutide will be administered once weekly subcutaneously.
Study: NCT06568042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05935748
Drug: NKT2152
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HIF2a inhibitor
Study: NCT04533347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.
Study: NCT05638672
Drug: Huashi Baidu Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granule is produced by Guangdong Yifang Pharmaceutical Co., Ltd. with a specification of 5g × 12 bags, twice a day, take 2 sachets each time with boiling water.
Study: NCT05706454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered orally twice a day
Study: NCT06137729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo.
Study: NCT06402123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral tablets
Study: NCT06376045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by SC injection.
Study: NCT05733286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer Suvorexant versus placebo every evening for Post-Operative Day (POD) 0,1, \&2
Study: NCT05564598
Drug: Anti-viral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive anti-viral therapy with one of the following:~4.2.2 Valganciclovir Dosing: 16 mg/kg/dose PO q12h OR 4.2.3 Ganciclovir Dosing: 6 mg/kg/dose IV q12h~Dose adjustments:~* Reduce dose by 50% for ANC less than 500 cells/mm3~* Hold the dose if ≤ 200 cells/mm3 until recovery ≥ 500 cells/mm3~* Treatment will continue for 6 months
Study: NCT06310967
Drug: IG3018
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06578052
Drug: Irinotecan liposome Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan liposome: intravenous infusion, day 1, every 2 weeks Capecitabine: oral, twice daily (bid), days 1 to 7, take for one week and then have a one-week interval.~Each 2-week period is considered a treatment cycle, with an expected treatment of 6 cycles. Subsequent maintenance treatment will be determined by the investigator's protocol until disease progression or intolerable toxicity occurs.
Study: NCT04855526
Drug: High THC/High CBD Marihuana
Approvals — FDA: no, EMA: no, PMDA: no
Description: high THC (65 mg THC) and high CBD (50 mg CBD)
Study: NCT04855526
Drug: No THC/No CBD Marihuana
Approvals — FDA: no, EMA: no, PMDA: no
Description: no THC (0 mg THC) and no CBD (0 mg CBD); placebo drug
Study: NCT05514847
Drug: Aspirin 81Mg Ec Tab
Normalized name: ASPIRIN 81MG EC TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
Study: NCT05514847
Drug: Aspirin 162Mg Ec Tab
Normalized name: ASPIRIN 162MG EC TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 162 mg enteric coated aspirin, taken daily from before 14 weeks of gestational age through pregnancy
Study: NCT04781543
Drug: HZN-825 BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral tablets BID
Study: NCT04781543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID
Study: NCT04781543
Drug: HZN-825 QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral tablets QD
Study: NCT06291064
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Epirubicin.
Study: NCT06291064
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is a pill that will be taken by mouth daily for 6 months after surgery is completed.
Study: NCT06470763
Drug: ANV600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANV600 administered by intravenous (IV) infusion
Study: NCT05659264
Drug: mRNA-0184
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-0184 dispersion for intravenous (IV) infusion
Study: NCT05513001
Drug: LOU064 (blinded)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOU064 (blinded) active treatment
Study: NCT05513001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06438367
Drug: [14C]TGRX-326
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy subjects will be given TGRX-326 60 mg orally on day 1.
Study: NCT05176951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inhalation using a capsule-based dry powder inhaler device.
Study: NCT05148286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the control group, 30 cc per kg of crystalloid will be administered according to the usual practice. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.
Study: NCT06102837
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional treatment in clinical
Study: NCT05525637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Match placebo tablets, once daily in the evening
Study: NCT06702202
Drug: Mixture of local anesthetics
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marcaine® (bupivacaine HCl) 0,5% and Xylocaine® (Lidocaine HCL) 2% = 2:1 Given in Femoropopliteal block group (Group F)
Study: NCT06700798
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750mg/m\^2
Study: NCT05111626
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6: 5-fluorouracil, leucovorin, and oxaliplatin will be administered as IV infusion.~OR CAPOX: oxaliplatin will be administered as IV infusion and capecitabine will be administered orally.
Study: NCT06438172
Drug: HCP1803-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT06438172
Drug: RLD2001-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT06438172
Drug: HPP2003-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug. Take it once daily for 8 weeks orally.
Study: NCT06568614
Drug: SYH2039
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYH2039 dosed orally
Study: NCT05395481
Drug: LY3849891
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05395481
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06365918
Drug: VG2025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by Intraperitoneal
Study: NCT06441227
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: single dose. Part 2: single dose with food effects. Part 3: single dose multiple doses.
Study: NCT06048120
Drug: BAY2701250 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single does, intravenous infusion
Study: NCT06048120
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for BAY2701250 IV
Study: NCT06048120
Drug: BAY2701250 SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, subcutaneous injection will be administered into abdominal subcutaneous fat tissue
Study: NCT06048120
Drug: Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for BAY2701250 SC
Study: NCT06132035
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will instill daily 1 package of Placebo eye drops in the study eye \[self-administered\] using the single use tear-off disposable packaging
Study: NCT04431999
Drug: Fractionated blood products transfusion
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe trauma patients with a life threatening bleeding will be managed with 3 packed red blood cells (PRBCs), 3 lyophilised plasma units and 1 dose of platelets for the 1st. The 2nd pack will consist of 3 packed red blood cells (PRBCs) and 3 lyophilised plasma units. Then, the later pack will consist of 3 packed red blood cells (PRBCs), 3 plasma units and 1 dose of platelets.
Study: NCT05313152
Drug: TAVO103A
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAVO103A single ascending dose IV infusion.
Study: NCT04484818
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04818632
Drug: AZD9833
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: AZD9833 monotherapy dose escalation.
Study: NCT04818632
Drug: AZD9833
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B: AZD9833 monotherapy dose expansion
Study: NCT06566794
Drug: Caffeine Tablet
Normalized name: Caffeine Tablets
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,5 x 100 mg tablet (50 mg caffeine).
Study: NCT06566794
Drug: Flurbiprofen Capsels
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 10 mg tablet.
Study: NCT06566794
Drug: Simvastatin tablets
Normalized name: Simvastatin Tablets
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 10 mg tablet.
Study: NCT06566794
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x placebo tablets in the Placebo Phase/Arm
Study: NCT06566794
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 x 50 mg tablet (three times daily for three days)
Study: NCT05562791
Drug: [68Ga]PSMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Gallium PSMA-PET/CT imaging within 10 days after standard of care FDG-PET/CT.
Study: NCT06107413
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Infusion
Study: NCT06030479
Drug: Warm saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin is incised midline sub-umbilical incision , bladder dissection will be done , uterus will be incised by vertical upper segment incision , followed by delivery of the baby.~Surgical assessment and decision for either conservative management or CS hysterectomy will be done.~After completion of surgical procedure , surgical field is observed for major bleeding and patients are subjected to intervention Packing the surgical field with towels fully saturated with warm saline solution ( 50 degrees).
Study: NCT05269706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo (Twice Daily)
Study: NCT06249152
Drug: QLS-111, 0.015%
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
Study: NCT06249152
Drug: QLS-111, 0.030%
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLS-111 eyedrops applied QPM for 14 days the BID for 14 days.
Study: NCT06249152
Drug: QLS-111 vehicle ophthalmic solution
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle drops applied QPM for 14 days the BID for 14 days.
Study: NCT06174922
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone for 4 months
Study: NCT05627479
Drug: GIK solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy cocktail of Glucose, Insulin and Potassium. The medications will be prepared as per standard protocol. Administered intravenously.
Study: NCT04838405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06701396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06489340
Drug: 2HPβCD
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2HPβCD is a 7 D-glucopyranosyl derivation of cyclodextrin (CD) that entraps and passively removes intracellular cholesterol from the kidney. It is also believed to promote active cholesterol removal through up-regulation of cholesterol efflux transporters ABCA1 and ABCG1.
Study: NCT06315530
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.
Study: NCT05178316
Drug: JZP150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of JZP150 once daily in the morning
Study: NCT05178316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of placebo once daily in the morning
Study: NCT05384119
Drug: Aromatase inhibitor (AI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT06007391
Drug: Nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nicotinamide 3g per day
Study: NCT05661552
Drug: Rosuvastatin 5mg
Normalized name: ROSUVASTATIN 5MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 5mg will be assigned to all participants
Study: NCT06513104
Drug: NNC0519-0130
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0519-0130 will be administered subcutaneously.
Study: NCT06513104
Drug: Levonorgestrel + Ethinylestradiol
Normalized name: levonorgestrel and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel + Ethinylestradiol will be administered orally.
Study: NCT04641273
Drug: BAY1817080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, intake orally.
Study: NCT04641273
Drug: Placebo for BAY1817080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, intake orally.
Study: NCT05991284
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: including SGLT-2 inhibitor and MRA
Study: NCT04665700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05115110
Drug: RO7204239
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7204239 will administered every 4 weeks (Q4W) by subcutaneous (SC) injection into the abdomen.~RO7204239 will be investigated at low- and high-dose in Part 1.
Study: NCT05115110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered Q4W by SC injection into the abdomen.
Study: NCT05187182
Drug: CA-4948
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provided by Curis, Inc.
Study: NCT05187182
Drug: mFOLFOX7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care
Study: NCT05260255
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: add on placebo ( 2 cap ) for 12 weeks
Study: NCT05800366
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Per standard care, via IV infusion
Study: NCT05800366
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Per standard care, via IV infusion
Study: NCT05463731
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV or SC
Study: NCT05724745
Drug: 3. Reversibility test with salbutamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reversibility test with salbutamol administered using a pressurized metered dose bottle and an inhalation chamber at a dosage of 100 μg, 4 times (i.e., 400 μg in total).
Study: NCT04093323
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04093323
Drug: PD-1 Ligand Inhibitor
Normalized name: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06307678
Drug: Calcium Hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: The samples were taken from the interstitial fluid of the apical tissues using 3 paper points before medicament placement.~Calcium hydroxide based medicament was placed in the canals using a file at a distance of 1 or 2 mm less than the root canal length.~At the second appointment, medicamentswere removed, and second samplingwas performed using the same method.~The RANKL/OPG, TNF alpha, TGF beta, PGE2 levels were measured by the enzyme-linked immunosorbent assay, and their ratio was calculated.
Study: NCT05327023
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HLA-matched: 50 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight. HLA haploidentical: 25 mg/kg IV once daily over 2 hours on days +3 and +4a Cyclophosphamide will be dosed according to ideal body weight.
Study: NCT06365632
Drug: Antispike gel, 100 g in a flask, produced by UNITEHPROM BSU, Republic of Belarus
Approvals — FDA: no, EMA: no, PMDA: no
Description: An antegrade appendectomy is performed, after which 50 to 100 ml of Antispike is applied in a thin layer to the surface of the cecum, the surface of adjacent organs and the parietal peritoneum of the right iliac region. The wound is sutured tightly.
Study: NCT05683548
Drug: REP 2139-Mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: REP 2139-Mg is the magnesium chelate complex of REP 2139
Study: NCT05828745
Drug: CB06-036
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB06-036 capsule
Study: NCT05828745
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT04433572
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo, including contrast medium with approximately 75 mg iodine per mL. The dosage will be delivered in a volume of 0.50 mL per cm of target lesion length, up to 30 cm, with +50% allowance for anatomical considerations; for a total volume of up to 22.5 mL and a total dose of up to 2.25 mg in participants assigned to treatment. The same volumes of comparator agent will be delivered in control participants.
Study: NCT05630872
Drug: DTG 50 mg orally QD plus TDF/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG 50 mg orally QD plus TDF/3TC from two weeks after completion of TB treatment to end of study (week 48).
Study: NCT05116709
Drug: BAT6005 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six dose groups were set up, including 10mg (initial dose) group, 30mg group, 100mg group, 300mg group, 600mg group and 900mg group, respectively.
Study: NCT05413902
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Study: NCT05413902
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Study: NCT05473858
Drug: OraVerse Injectable Product
Normalized name: OraVerse Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of oraverse,
Study: NCT06577025
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered intravenously as a part of conditioning regimen.
Study: NCT06282445
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2, po, bid, d1-14, Q3W Maintenance therapy: 1250mg/m2, po, bid, d1-14, Q3W
Study: NCT06365853
Drug: Prednisolone acetate ophthalmic suspension 1% eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of prednisolone acetate ophthalmic suspension 1% eye drops as prescribed by the treating physician.
Study: NCT05331885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains only excipients